Formosa and Tabuk sign deal for FDA-approved ophthalmic suspension [Yahoo! Finance]
Eyenovia, Inc. (EYEN)
Last eyenovia, inc. earnings: 3/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=254685&p=irol-irhome
Company Research
Source: Yahoo! Finance
the clobetasol propionate ophthalmic suspension, 0.05% (APP13007) to treat inflammation and pain after ocular surgery. APP13007 will be commercialised in key Middle East and North Africa (MENA) regions. The deal comes after the ophthalmic suspension obtained approval from the US Food and Drug Administration (FDA) in March 2024. The agreement includes upfront payments and milestone payments on meeting commercialisation and sales-based goals, other than additional considerations, throughout the deal's term. APP13007 utilises Formosa Pharma's APNT nanoparticle formulation platform and contains clobetasol propionate, a superpotent corticosteroid. This formulation offers a convenient dosing regimen, requiring administration only twice daily for 14 days, while offering quick and lasting inflammation and pain relief. Tabuk Pharmaceuticals CEO Ismail Shehada stated: “We are excited at Tabuk to be partnering with Formosa to introduce this innovative drug for our patients in Saudi A
Show less
Read more
Impact Snapshot
Event Time:
EYEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EYEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EYEN alerts
High impacting Eyenovia, Inc. news events
Weekly update
A roundup of the hottest topics
EYEN
News
- All You Need to Know About Eyenovia (EYEN) Rating Upgrade to Buy [Yahoo! Finance]Yahoo! Finance
- Eyenovia, Inc. (NASDAQ: EYEN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.MarketBeat
- Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol [Yahoo! Finance]Yahoo! Finance
- Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and ClobetasolGlobeNewswire
- Eyenovia to Report First Quarter 2024 Results on Wednesday, May 15thGlobeNewswire
EYEN
Earnings
- 5/15/24 - Beat
EYEN
Sec Filings
- 5/16/24 - Form 424B5
- 5/16/24 - Form 8-K
- 5/15/24 - Form 8-K
- EYEN's page on the SEC website